Imagion Biosystems Limited has released the Renounceable Rights Issue Prospectus:
For a renounceable pro rata offer of 204,512,879 Shares at an issue price of $0.01 each on the basis of 2 Shares for every 5 Shares held at the Record Date, together with a free attaching New Option on a one for one basis, to raise up to $2,045,129, partially underwritten to $500,000.
Read the Renounceable Rights Issue Prospectus.
MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, today announced the appointment of Mr Brett Mitchell
Download a copy of the AGM 2024 presentation deck HERE. AGM 2024 Video Transcript: Good morning, ladies and gentlemen. My name is Robert Crew and
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal
We’re on a mission to make cancer more detectable.
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance